research teams from the Rocky Mountain Alzheimer’s Disease Center (RMADC) presented their recent research findings — spanning a wide range of topics — at the
2018 Alzheimer’s Association International Conference®
(AAIC) in Chicago July 22–26. Many RMADC members played key roles in more than
one of these projects, showing our innovative spirit and our commitment to
engaging in strong team science that will help us prevent, diagnose and treat
the many forms of dementia.
GM-CSF/Leukine® Talks and Posters
Director Huntington Potter, PhD, gave a platform presentation sharing an
update on data from the Phase II human trial to determine the safety and
efficacy of GM-CSF/Leukine® in mild-to-moderate Alzheimer’s disease
(AD). RMADC co-authors include Drs. Jonathan Woodcock, Timothy Boyd, Stefan
Sillau, Thomas Borges, Brianne Bettcher and Ashesh Thaker, as well as Ramesh
Karki, Joseph Daniels and Kate Heffernan. Dr. Timothy Boyd presented a
poster describing blood biomarker changes in subjects from the Phase II GM-CSF/Leukine®
trial, as well as investigation into whether the Leukine®-associated
changes in biomarker levels also correlate with brain or symptom changes
associated with AD. RMADC co-authors include Drs. Potter, Woodcock, Sillau, Borges,
and Bettcher, together with Vanesa Adame, Joseph Daniels and Kate Heffernan.
Md. Mahiuddin Ahmed presented a poster showing his finding that GM-CSF
treatment can reverse some of the memory deficits in a mouse model of Down
syndrome; RMADC co-authors include Drs. Huntington Potter, Athena Ching Jung
Wang, Timothy Boyd and Mihret Elos.
Samantha Holden and Victoria Pelak presented a poster focused on the
relationships between cognitive impairment, subjective visual symptoms, and
objectively measured “convergence insufficiency”, which is a term used to
describe an inability to coordinate binocular eye movements to maintain single
vision during near target viewing and is most often reported by patients as
double vision, in patients with Parkinson’s disease.
Luis Medina presented a poster describing his pilot study using three
performance-based functional assessments in normal aging and mild cognitive
impairment subjects to determine the sensitivity of daily function assessments
to detect age- and Alzheimer’s-related brain changes. RMADC co-authors include
Drs. Brianne Bettcher and Chris Filley, together with Kate Heffernan.
Aneuploidy in Huntington's disease
Elos, M.S., presented a poster showing that brain cells and fibroblast cell
lines from Huntington’s disease patients show elevated levels of aneuploidy
(abnormal numbers of chromosomes). RMADC co-authors include Drs. Julbert Caneus,
Heidi Chial and Huntington Potter.
Odor Recognition for Predicting Decline
Dr. Peter Pressman presented a poster describing his studies of whether odor
recognition — using ground coffee as a non-standardized, inexpensive, readily available and reusable odor — may be useful for predicting
cognitive decline. RMADC co-authors include Drs. Jonathan Woodcock and Chris
so many RMADC team members presenting at this key conference underscores the
international scientific community’s interest in the work we are doing, and in
the insights this research will add to our global understanding of these